Sodium Glucose Cotransporter 2 Inhibitors.
Med Clin North Am. 2015 Jan;99(1):131-143
Authors: White JR
This article provides an overview of the physiologic basis, pharmacology, and current clinical experience with sodium glucose cotransporter 2 (SGLT2) inhibitors. It details the role of the kidneys in glucose homeostasis and the impact on that regulatory system of the use of SGLT2 inhibitors. The article also includes an overview of the impact of SGLT2s on glycemic control in patients with diabetes. In addition, it outlines the potential benefits and problems encountered with the use of these agents.
PMID: 25456647 [PubMed - as supplied by publisher]Link to Article at PubMed